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ABSTRACT
Human papillomavirus type 6 (HPV6) is the major etiologic agent of genital warts and recurrent respiratory
papillomatosis. Although the commercial HPV vaccines cover HPV6, the neutralization sites and mode for HPV6 are
poorly understood. Here, we identify the HPV6 neutralization sites and discriminate the inhibition of virus
attachment and entry by three potent neutralizing antibodies (nAbs), 5D3, 17D5, and 15F7. Mutagenesis assays
showed that these nAbs predominantly target surface loops BC, DE, and FG of HPV6 L1. Cryo-EM structures of the
HPV6 pseudovirus (PsV) and its immune complexes revealed three distinct binding modalities – full-occupation-
bound to capsid, top-center-bound-, and top-rim-bound to pentamers – and illustrated a structural atlas for three
classes of antibody-bound footprints that are located at center-distal ring, center, and center-proximal ring of
pentamer surface for 5D3, 17D5, and 15F7, respectively. Two modes of neutralization were identified: mAb 5D3 and
17D5 block HPV PsV from attaching to the extracellular matrix (ECM) and the cell surface, whereas 15F7 allows PsV
attachment but prohibits PsV from entering the cell. These findings highlight three neutralization sites of HPV6 L1
and outline two antibody-mediated neutralization mechanisms against HPV6, which will be relevant for HPV virology
and antiviral inhibitor design.
Highlights
. Major neutralization sites of HPV6 were mapped on the pseudovirus cryo-EM structure
. mAb 15F7 binds HPV6 capsid with a novel top-rim binding modality and confers a post-attachment neutralization
. mAb 17D5 binds capsid in top-centre manner but unexpectedly prevents virus from attachment to cell surface
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Introduction
Human papillomavirus (HPV) infection is a leading
cause of genital warts and cervical cancer [1]. More
than 200 genotypes of HPV have been identified
based on the homology of the major capsid protein,
L1 [2]. According to its propensity to cause cervical
cancer, HPV is classified into low- or high-risk types.
HPV6 and HPV11 are two major types of low-risk
HPV and are responsible for over 90% of genital
warts [3–9]. There are three commercially available
HPV prophylactic vaccines: Cervarix, Gardasil 4, and
Gardasil 9; the latter two contain HPV6 and 11 anti-
gens, which can provide protection against HPV6
and 11 infection with high efficacy [10, 11], however,
these vaccines offer little therapeutic benefit against
existing infection.
The current vaccines on the market were designed
based on the mode of self-assembly of L1 to form
virus-like particles (VLPs). L1 can interact with cellular
receptors, such as heparan sulfate proteoglycans
(HSPGs) or laminin-332 on the cell surface to drive
primary viral attachment to host cells [12]. The HPV
minor structural capsid protein, L2, on the other
hand, is involved with cell entry and viral genome
escape [13]. The L1 protein alone or together with L2
can assemble into VLPs [14], and induce a strong
immune response from the host against infection
[15]. The 55∼60-nm diameter HPV capsid is com-
posed of 72 L1 protein pentamers, each consisting of
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five copies of L1 [16], and an uncertain number of L2
proteins. Twelve of the pentamers lie on the icosahe-
dral 5-fold axes (pentavalent capsomers), while the
other 60 pentamers are positioned at the pseudo 6-
fold axes (hexavalent capsomers) [17]. Crystal struc-
tures of L1 pentamers (HPV11, -16, -18, and -35)
have illustrated that the HPV L1 monomer forms a
canonical, eight-stranded-barrel (BIDG-CHEF) linked
by six highly variable loops (BC, CD, DE, EF, FG,
and HI)[18]. These surface loops, except CD, contain
the highest sequence variation among the different
HPV types and play a critical role in eliciting the
responses of protective antibodies by the host. As
such, most of the neutralizing epitopes have been
identified at these hypervariable loops, with various
sites recognized by type-specific neutralizing anti-
bodies (nAbs) [17, 19, 20].
To establish infection, HPV undergoes a compli-
cated process that includes receptor binding, a post-
attachment conformational change, furin cleavage,
and internalization [21]. HSPGs, located on the base-
ment membrane in the tissues, are the primary recep-
tors for HPV infection, and facilitate upstream
events, including the initial attachment and confor-
mational changes of the capsid protein [22, 23]. Co-
crystallization of HPV16 with heparin revealed four
distinct heparin binding sites that were critical for the
conformational changes that permit virus access and
mediate downstream events, including secondary bind-
ing site exposure, transfer to the uptake receptor, and
capsid uncoating [23]. In addition to HSPGs, several
other cellular receptors have been identified, such as
α6 integrin, growth factor receptors, cyclophilin B
(CyPB), laminin-332 and annexin A2 [24, 25]. How-
ever, the specific details of these interactions remain
unclear.
Virus neutralization is defined as an abrogation of
virus infection through antibody-virus associations.
Previous studies have highlighted the different neutral-
ization mechanisms mediated by HPV nAbs [26].
Antibodies such as HPV16.V5 and HPV16.E70 do
not prevent virus from binding to the primary cellular
attachment receptor (HSPG), but are proposed to block
the subsequent shift to engage other co-receptors [23].
Other Abs, such as HPV16.U4, may interfere with the
virus-HSPG/receptor interaction or the ensuing endo-
cytic process [26, 27]. Cryo-EM structures of the HPV
capsid in complex with nAbs indicate that, for most
nAbs, the core binding epitopes involve distinct surface
loops of the L1 protein: FG loop (HPV16.V5,
HPV16.E70, HPV59.28F10), HI loop (HPV16.V5,
HPV16.E70), and DE loop (HPV58.A12A3). In con-
trast, HPV16.U4 uniquely recognizes the C-terminal
arm of L1. Amino acid residues 49–54 and 169–178
of HPV6 L1 are the principal regions for HPV6 type-
specific antibody recognition, as identified via studies
with the cottontail rabbit papillomavirus (CRPV)/
HPV6-hybrid L1 protein [28]. Yet, and in part due to
a lack of high-resolution structural information, the
exact epitopes involved in HPV6 neutralization
remains unknown, as does the molecular mechanism
of the interaction.
In this study, we tested three potent neutralizing
antibodies against HPV6 using epitope mapping and
structural analysis. Through homologous loop-
swapping of the L1 protein between HPV6 and
HPV16, we identified the BC, DE, and FG loops
as the key surface loops responsible for type-specific
antibody recognition. To verify the variability in
binding, we constructed cryo-EM structures of
HPV6 PsV complexed with Fabs and unveiled the
epitope locations targeted by these nAbs. Using
immunofluorescence, we identified three patterns
of binding and overall two modes of neutralization.
Overall, these findings offer insight into the mech-
anism(s) of low-risk HPV neutralization mediated
by antibodies.
Materials and Methods
Cell lines
HaCaT cells and 293FT cells were cultivated in Dulbec-
co’s modified Eagle’s medium supplemented with 10%
fetal bovine serum (FBS). These cells were used for
HPV6 PsV production (293FT cells), immunofluores-
cence microscopy (HaCaT cells), and the PsV neutral-
ization assay (293FT cells).
Monoclonal antibodies (mAbs)
BALB/c mice for hybridoma preparation were immu-
nized subcutaneously three times with HPV6 VLPs
absorbed with aluminum adjuvant as described in
our previous study [29]. A set of anti-HPV6 murine
mAbs were generated by ascites fluid in a standard
hybridoma assay and screened by enzyme-linked
immunosorbent assay and pseudovirus-based neutral-
ization assay. These antibodies were affinity-purified
on Protein A columns. The concentrations of the pur-
ified murine IgGs were determined at OD280nm before
dilution in PBS and storage in a final concentration of
1.0 mg/ml at −20°C.
Preparation of the HPV6 PsV
HPV6 PsVs were produced as described in our pre-
vious study [29]. The L1/L2 expression vector
p6sheLLr (No. 37318) was obtained from Addgene
and reporter plasmid pN31-EGFP was kindly provided
by Dr.J.T.Schiller [30]. The plasmids encoding HPV6
L1 and L2 proteins and the reporter plasmid were co-
transfected into 293FT cells. 293FT cells were har-
vested 72 h after transfection, lysed in lysis buffer
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containing 0.5% Brij58 (Sigma-Aldrich), 0.2% Benzo-
nase (Merck Millipore, Darmstadt, Germany), 0.2%
PlasmidSafe ATP-Dependent DNase (Epicenter Bio-
technologies, Madison, WI), and Dulbecco’s phos-
phate-buffered saline (DPBS)-Mg solution, and then
incubated at 37°C for 18 h. Lysates were then combined
with 5 M NaCl. PsV titers were determined using the
tissue culture infective dose (TCID50) values, measured
using the Reed-Muench method [31].
Construction and purification of HPV6-16
chimeric VLPs
We replaced each of the surface loops of the HPV6 L1
protein with the homologous loops of the HPV16 L1
protein separately, hereafter referred to as HPV6-16
chimeric VLPs. Genes encoding the HPV16 loop
(BC, DEa, DEb, DEc, EF, FGa, FGb, FGc, HIa, HIb)
were cloned into pTO-T7-HPV6 L1 to replace HPV6
loops by Gibson Assembly [29]. The recombinant plas-
mids were transformed into E.coli ER2566 strain for
the expression of the HPV6-16 loop mutant VLPs.
The transformed cells were cultured in LB medium at
37°C overnight, and protein expression was induced
by the addition of isopropyl-β-D-thiogalactoside at
25°C for 8 h. Bacterial cells were collected by cen-
trifugation and re-suspended in cell lysis solution
(20 mM Tris, pH 7.2, 300 mM NaCl, 10 mM
EDTA). After sonication, the target proteins were
released from cells and were separated by centrifu-
gation. The lysate supernatant was combined with
20 mM DTT to denature the protein. Target proteins
were purified using an SP Sepharose 4 Fast Flow col-
umn (GE Healthcare) and eluted with a solution con-
taining 20 mM PB8.0, 20 mM DTT and 800 mM
NaCl. Proteins were further purified using a CHT-II
column (Bio-Rad), with elution in 20 mM PB8.0,
20 mM DTT and 1 M NaCl. Protein purity was
assessed using sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), according
to the Laemmli method.
Enzyme-linked immunosorbent assay (ELISA)
HPV6-16 chimeric VLPs and HPV6 wild-type VLPs
were coated into the wells of a 96-well microplate at
a concentration of 300 ng per well and then incubated
with serial dilutions of each monoclonal antibody at
37°C for 45 min. The wells were washed, incubated
with HRP-conjugated goat anti-mouse IgG at 37°C
for 45 min, and then washed again. Tetramethylbenzi-
dine substrate (100 μl) was added to each well and the
plates incubated at 37°C for 10 min. The reaction was
stopped with 2 M H2SO4, and the OD values were
measured at 450 nm, with a reference wavelength of
620 nm. GraphPad Prism 7 was used to assess the
median effective concentration (EC50) of each mono-
clonal antibody.
Transmission electron microscopy (TEM)
The morphologies of the HPV6-16 chimeric VLPs
diluted to 200 μg/ml were analyzed by negative staining
TEM using an FEI Tecnai Spirit TEM at 120 kV and
imaged at approximately 25,000× magnification. The
approach was used to confirm the full-length anti-
bodies capable to bind HPV6 VLPs as well, the samples
were prepared by incubating the HPV6 VLP
with excessive amount of full-length antibodies at 37°
C for 2h.
Pseudovirus-based neutralization assay (PBNA)
293FT cells were cultured in 96-well plates at a density
of 1.5 × 104 cells per well and incubated at 37°C for 4
h. Monoclonal antibody samples were diluted from
1,000–0.488 ng/mL with two-fold serial diluent
(DMEM) and the PsVs were diluted to 2 × 105
TCID50/μl. Equal volumes (60 μl) of PsV diluent and
the serially diluted antibodies were mixed in each
well, and incubated at 37°C for 1 h. 293FT cells were
then incubated with 100 μl of the mixtures at 37°C
for 72 h. The median inhibitory concentration (IC50)
was defined as the antibody concentration for achiev-
ing 50% inhibition of PsV.
Immunoflurescence microscopy
HaCaT cells were seeded onto coverslips in 24-well
plates and incubated for 48 h. To study the binding
model, the PsV (200 ng) was incubated with mono-
clonal antibodies at a neutralization dose at 37°C for
1 h and then added to the prepared HaCaT cells for
1 h at room temperature. Cells were then fixed in 4%
paraformaldehyde in PBS. For the detection of anti-
body-bound particles, the cells were stained with
Alexa Fluor 488-conjugated donkey anti-mouse IgG.
For the detection of particles mixed with BSA, the
cells were stained with a mouse polyclonal antiserum
raised against HPV6 and subsequently stained with
Alexa Fluor 488-conjugated donkey anti-mouse IgG.
Rhodamine-conjugated phalloidin was used to delin-
eate the cell body.
To evaluate the ECM-binding model, the ECM was
firstly prepared as described below. Briefly, HaCaT cells
were seeded onto the coverslips for 48 h and then were
then removed by lysis buffer digestion (0.5% Triton X-
100, 10 mM NH3·H2O, 1 unit/ml Dnase-I in PBS). The
coverslips were washed three times with PBS, leaving
the ECM on the coverslips. PsV pre-incubated with
monoclonal antibody were added to the ECM, which
was subsequently fixed in 4% paraformaldehyde in
PBS. The antibody-bound particles were detected
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with Alexa Fluor 488-conjugated donkey anti-mouse
IgG. Laminin 5 was detected with a rabbit polyclonal
antiserum and Alexa Fluor 594-conjugated donkey
anti-rabbit IgG. In all cases, the cells were counter-
stained with 4’,6-diamidino-2-phenylindole (DAPI).
All immunofluorescence images were captured using
a Zeiss LSM 780 confocal system. Images were pro-
cessed with Adobe Photoshop software.
Cryo-EM and three-dimensional (3D)
reconstruction
To prepare the PsV-Fab immune complexes, the pur-
ified HPV6 PsV was mixed with an oversaturated
amount of Fab and then incubated at 37°C for 2
h. The sample (2 μl) was pipetted onto a glow-dis-
charged Quantifoil holey carbon grid (R2/1, 200
mesh; Quantifoil Micro Tools) in a FEI Vitrobot. For
the HPV6:5D3 and HPV6:17D5 complexes, cryo-EM
images were collected on a FEI Falcon 2 direct detector
camera using a FEI TF30 FEG microscope operated at
300 kV at a 93,000× nominal magnification. The elec-
tron dose was determined at 25 e-/Å2. Robem was used
to box and extract the particles [32]. Complex image
processing and 3D reconstruction were completed
using Relion and AUTO3DEM programs [32]. For
the HPV6 particles and the HPV6:15F7 complex, a Fal-
con 3 direct detector camera and cisTEM were used to
complete the above work. For a higher resolution struc-
ture of the HPV6 particle, we reconstructed subareas
surrounding the 2-fold axes of the icosahedral HPV6
capsid using Relion and cisTEM.
HPV6 model building and fitting of HPV6
particles and Fab
The cryo-EM structure of the HPV16 virus protomer
(PDB ID:5KEP) was used for homology modeling
and fitted by Chimera [33] into the corresponding
volume of the subparticle density map. Coot [34] and
Phenix [35] were used to modify and refine the atomic
positions. Chimera was used for visualization and seg-
mentation of the density maps [33]. The HPV6 particle
model and the crystal structure of the Fab (PDB
ID:3RKD) were fitted into the immune complex
maps by the “fit in the map” command in UCSF Chi-
mera. Fab density in the cryo-EM maps were projected
on a stereographic sphere by RIVEM [36].
Data bank accession numbers
Atomic coordinates of HPV6 particle have been sub-
mitted to the Protein Data Bank with accession num-
ber 6L31. The cryo-EM density maps for HPV6
subparticle, HPV6 particle alone and in complex with
antibodies have been deposited in the Electron
Microscopy DataBank (EMDB: EMDB-0816, EMDB-
0817, EMDB-0818, EMDB-0819, EMDB-0820).
Results
Binding region profiles of potent HPV6 nAbs
We first sought to investigate the epitope structural
characteristics and neutralization mechanism of
HPV6 nAbs, selecting the five most potent nAbs
(10H1, 17D5, 11B10, 5D3, and 15F7) and two non-
neutralizing antibodies (2D4 and 18E4) from a panel
of HPV6 type-specific murine mAbs that was gener-
ated in our previous work [29]. As expected, the five
neutralizing antibodies showed high neutralizing
efficiency (IC50 < 10 ng/ml) against the HPV6 PsV in
the PBNA assay. However, mAb 15F7 exhibited a
slightly lower neutralization activity (8.81 ng/ml)
than the other mAbs (Figure 1A); a similar difference
for 15F7 was also noted in the binding efficiency
against HPV6 VLP in the EC50 assay (Figure 1B). As
expected, the non-neutralizing antibodies, 2D4 and
18E4, showed no neutralization activity.
The viral epitopes that induce the production of
nAbs against HPV are mainly located on the surface
loops of the L1 protein [27, 37, 38, 39]. To identify
which surface loops of HPV6 L1 are crucial for mAb
recognition, we genetically substituted the surface
loops or subloops of HPV6 L1 with corresponding
ones of HPV16 L1 (BC, DEa, DEb, DEc, EF, FGa,
FGb, FGc, HIa, HIb), and generated 10 chimeric
HPV6-16 VLPs: H6-16BC, H6-16DEa, H6-16DEb,
H6-16DEc, H6-16EF, H6-16FGa, H6-16FGb, H6-
16FGc, H6-16HIa, H6-16HIb (Figure 1C and Figure
S1A). Of note, loop-swapping for the DE, FG, and HI
loops, which have relatively long sequences, was under-
taken using subloops instead of the full sequence (DEa,
DEb, DEc, FGa, FGb, FGc, HIa, HIb) to obviate any
potential dramatic conformational changes that could
occur upon long loop replacement. All chimeric
VLPs assumed good self-assembled morphologies and
comparable size with respect to the wild-type HPV16
and HPV6 VLPs in negative-staining TEM (Figure
S1B). The potential binding regions for the mAbs
against the HPV6 capsid were determined by variations
in the EC50 values between the WT and loop-swapped
chimeras in an ELISA assay (Table S2). We then
plotted a heat map using the EC50 changes to illustrate
the differences in the binding region profiles of the
mAb; a threshold of >5-times indicates a substantially
important effect of the loop/subloop swap (Figure
1D). The heat maps showed binding at the following
regions of each mAb: 2D4 shows binding at the BC,
DE, EF, and FG loops; 18E4 at least at EF and FG
loops; 10H1 at BC, DE, FG, and HI loops; 17D5 at
BC, DE, and FG loops; 11B10 at BC and FG loops;
5D3 at the FG loop; and 15F7 at DE and EF loops.
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Intriguingly, among the different antibodies, all five
surface loops (BC, DE, EF, FG, and HI) of HPV6 L1
contributed to antibody recognition, with loops BC,
DE, and FG predominantly associated with nAb bind-
ing. Importantly, the FG loop has critical sites for the
binding of potent mAbs, as indicated by the loss of
reactivity for six of the seven mAbs in the FG-swapped
HPV6 VLPs. This loop profile appears to reflect the
results from other studies of the well-characterized
HPV16 and HPV59 [17, 38].
Neutralization mechanism of HPV6 nAbs
HPV infection is multifaceted and includes stages of
host cell attachment, entry and intracellular trafficking.
Neutralizing antibodies are believed to interfere with at
least one of these stages [40]. To elucidate how nAbs
perturb the route of HPV6 PsV infection, HPV6 PsV
activity was traced in HaCaT cells by immunoflures-
cence microscopy. The PsV was bound to the ECM
or cell surface in the presence of an nAb, a non-neutra-
lizing mAbs, or bovine serum albumin (BSA, negative
control), and the fluorescence of the attached PsV
was quantified by averaging the pixel numbers in 10
randomized microscopy views. BSA values were used
for normalization.
For the ECM attachment test, non-neutralizing
mAbs (2D4 and 18E4) had minimal effect on
prohibiting PsV attachment, as evidenced by highly
positive green staining of the PsV in the ECM
(Figure 2A, upper left panel). This is compared with
the merged images showing the superimposition of
the ECM in red and the PsV in green (Figure 2A,
lower left panel). There is a comparable amount of
attached PsV in the presence of either the non-neutra-
lizing mAbs or the BSA negative control (Figure 2C).
By comparison, four nAbs (10H1, 17D5, 11B10, and
5D3) were able to almost completely inhibit HPV6
PsV attachment to the ECM. Intriguingly, nAb 15F7
did not perturb PsV attachment to the ECM, with
values similar to the non-neutralizing mAbs (Figure
2A right panel and Figure 2C). Finally, the inhibitory
profile for cell surface attachment (Figure 2B and D)
was almost identical to that for ECM attachment.
Cryo-EM structure reconstruction of HPV6 PsV
To identify the neutralization sites on the HPV6 capsid,
we first prepared the HPV6 PsV alone according to our
previous protocol [41] followed by vitrificaton and sub-
sequent cryo-EM structure reconstruction. (This PsV
preparation will later be used for various immune com-
plexes with the aforementioned HPV6 nAbs.) The PsV
displayed as homogeneous particles in the view of low-
dose cryo-EM images (Figure 3A). We finally resolved
the structure at a resolution of 5.5 Å, as determined by
Figure 1. Characterization of a HPV6 mAb panel. (A) Neutralization efficiency, reflected as IC50, was determined through pseudo-
virus-based neutralization assay (PBNA). (B) Binding activity, reflected as EC50, was determined using an enzyme-linked immuno-
sorbent assay (ELISA) using HPV6 VLPs. (C) Schematic representation of the constructs of the wild-type and chimeric HPV6-16 L1
proteins. Sequences of the five surface loops for each WT or mutated L1 protein are indicated. (D) Epitope analysis of seven mAbs
displayed as a heat map. The colours ranging from white to blue denote the increase in EC50 value in the ELISA. Darker shades of
blue indicate critical regions for mAb binding.
Emerging Microbes & Infections 1725
the gold-standard Fourier shell correlation (FSC), with
a cutoff threshold of 0.143 (Figure S3, Table S1). Like
previous overall structures of HPV particles [16, 17,
27, 38, 42], the HPV6 capsid displayed a T = 7d icosa-
hedral structure, with a diameter of 58 nm, and the
capsomers exhibited a pronounced star-shaped mor-
phology (Figure 3B and C). The pentamer of HPV6
was easily identifiable, and “suspended bridges” (com-
prising the C-terminal arm of L1 proteins) connecting
neighboring pentamers were conspicuous in the den-
sity map (Figure 3C).
The structure of the HPV6 PsV was further
improved to 4.18 Å resolution by subparticle refine-
ment (Figure 3D, S3); this allowed us to build a near-
atomic model of the T = 7 HPV6 PsV structure, using
the crystal structure of the HPV16 capsid (PDB
ID:5KEP) as a starting model. The built model was
refined with Phenix [35] (Figure 3G). In the structure,
the HPV6L1 monomer exihibited well-resolved α-helix
and β-sheet core regions and interpretable loop regions
(Figure 3E). Overall, the asymmetric unit of the HPV6
model had a very similar core region to that of HPV16,
with a root mean square deviation [RMSD] of 1.95 Å
for all C-α atoms of L1. However, there were promi-
nent differences in the surface loops and suspended
bridges in the structural alignment (Figure 3F),
believed to be associated with genotype specificity
[41, 42].
Cryo-EM reconstruction of HPV6 PsV in complex
with nAbs
To localize the neutralization sites on the HPV6 capsid,
we next determined the structures of the HPV6 PsV
Figure 2. Attachment assay for HPV6 mAbs to the ECM and cell surface. HaCaT cells were prepared on coverslips for 48 h and then
incubated with the HPV6 PsV premixed with each of the mAbs (five neutralizing mAbs and two non-neutralizing mAbs). Staining
was performed with Alexa Fluor 488 (green). The PsV incubated with BSA served as the negative control. DAPI (blue) was used to
stain for cell nuclei, laminin-5 (red) for the ECM in the ECM-binding assay (A), and phalloidin (red) for activity in the cell-surface
binding assay (B). For each mAb, the merged images are shown in the lower panel and the PsV (green) in the upper panel. All
images were quantified via LSM software (Zen) and ImageJ. (C, D) The pixel sum for virus bound with antibody is shown relative
to that for virus with BSA control. ***P < 0.0001.
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complexed with different nAbs by cryo-EM. Five
potent nAbs (5D3, 17D5, 15F7, 11B10, 10H1) were
used in the preparation of the immune complexes.
For unknown reasons, Fabs 10H1 and 11B10 were
not discernible, either in low-dose cryo-EM images or
after 2D classification of selected particles (Figure
S2). Thus, we only obtained structures for three
immune complexes, HPV6:17D5, HPV6:5D3, and
HPV6:15F7 at resolutions of 11.94, 16.55, and 4.36 Å,
respectivley (FSC cutoff of 0.143; Figure S3, Table S1).
Interestingly, we observed three different modalities
of Fab binding in the cryo-EM reconstructions of the
three immune complexes. In the case of Fab 5D3 bind-
ing, five Fabs engaged with each capsomer, with a total
of 360 Fabs decorating the entire capsid in a full-occu-
pation manner. However, the densities ascribable to the
Fabs bound to the 5-coordinated pentamers were
weaker than those of the 6-coordinated Fabs, which
might be due to steric clashing of the five Fabs residing
in the relatively smaller outside space of the 5-coordi-
nated pentamers compared with the 6-coordinated
ones (Figure 4A, D, G); this situation was also observed
in the reported cryo-EM structure of the immune com-
plex HPV16.V5 in a previous study [17]. In contrast, a
single Fab 17D5 binds to the centre of the HPV6 pen-
tamer, with a nearly vertical orientation against the
pentamer surface, a so-called top-centre binding
mode (Figure 4B, E and H); we previously reported a
similar binding for the crystal structure and cryo-EM
structure of the HPV58.A12A3 complex [38]. Finally,
unlike previously resolved HPV capsid–antibody bind-
ing modalities, we observed a unique mode of binding
for 157F. We show that five 15F7 Fabs cluster inten-
sively around each pentamer (top-rim binding mode)
with 360 Fabs decorating the capsid as 72 five-spade
petals (Figure 4C, F and I). Thus, 15F7 binding may
reflect a new mode of antibody binding in the neutral-
ization of the HPV capsid.
Next, the aforementioned model of the HPV6 PsV
and the crystal stucture of a murine monoclonal anti-
body Fab (PDB: 3RKD) were fitted into cryo-EM elec-
tronic density maps of the immune complexes for
further epitope analysis. Similar to the cryo-EM struc-
ture of HPV16:V5 and HPV58:28F10 complexes [16,
38], six different 5D3 Fabs – located on six monomers
in the asymmetric unit of the capsid – exhibited varied
occupancies in the density map of HPV6:5D3
(Figure 5A). Upon rigid fitting of HPV6, a steric
clash was observed between Fab-1 from the 5-coordi-
nated pentamer and Fab-2 from the 6-coordinated
pentamer (Figure 5D). However, adjacent Fabs within
one pentamer, e.g. Fab-2 and Fab-6, showed no steric
interference with each other (Figure 5E). It is reason-
able to propose that 5D3 can freely bind to locations
3, 4, 5, and 6 and prefer to attach to location 2 rather
than location 1 because of a stronger density for Fab-
2 than for Fab-1.
In the case of HPV6:17D5, we found two combined
densities linking the Fab with monomer 1 and 2 in the
6-coordinated pentamer (Figure 5B and F). According
to the fitting result (Figure 5G), we infer that 17D5 can
attach to the HPV6 capsid in a specific orientation.
Unlike 5D3, 15F7 Fab clustering around each pentamer
(including 5-coordinated and 6-coordinated ones) is
Figure 3. Cryo-EM reconstruction of HPV6 PsV at near-atomic resolution. (A) Representative cryo-EM images of the vitrified HPV6
PsV. (B) Density maps coloured according to the distance from the centre of the capsid: red, 220 Å; yellow, 250 Å; green, 270 Å; cyan,
290 Å; and blue, 330 Å. (C) Zoomed-in view of the HPV6 PsV includes a 5-coordinated pentamer (black pentagon) and a 6-coordi-
nated pentamer (black hexagon). (D) Subparticle reconstruction of HPV6 PsV at the region of the 2-fold axes of icosahedral sym-
metry. (E) One HPV6 L1 monomer of the near-atomic model was fitted into the corresponding density map. (F) Structural
comparison of the asymmetric units between the HPV6 (red) and HPV16 (blue) models. (G) Complete near-atomic model of
HPV6 is shown in ribbon representation. Two-, three-, and five-fold axes of icosahedral symmetry are indicated as a black ellipse,
triangle, and pentagon, respectively.
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distant and free from any interaction with other Fabs
bound to neighboring pentamers (Figure 5C). In
addition, the five Fabs might associate with each neigh-
boring other within one cluster, as noted by their close
positions in both the cryo-EM density map and the
fitted model (Figure 5H and I); the 5-fold association
of five capsid-bound Fabs has been observed previously
in the atomic structure of the coxsackievirus A6
immune complex [43]. In addition, the variable
domains of the bound 15F7 Fab have a stronger density
than those of the other two Fabs, which suggests full
occupation of the binding sites of 15A7 Fab on the
HPV6 capsid.
The potential bivalent binding of full-length anti-
body for all the three mAbs was analyzed by modeling
the full-length antibody and measuring the distance
between two most closely adjacent Fabs bound to the
capsid. Interestingly, it is possible for mAbs 5D3 and
15F7 to bivalently bind to a single particle. However,
both Fabs of one full-length antibody 17D5 cannot
simultaneously bind to a single capsid due to long dis-
tance (ranging 154–169 Å) between two neighboring
bound Fabs (Figure S4). In addition, negative staining
TEM assay of VLP:nAbs complexes confirmed the neu-
tralizing antibodies could bind to HPV6 capsid in full-
length form as well as their Fabs did in cryo-EM. Intri-
guingly, non-neutralizing antibodies 2D4 and 18E4
could not bind HPV6 VLPs (Figure S5), which is
inconsistent with that they were well reactive in VLP-
based ELISA binding assay (Figure 1B). On the other
hand, they were identified to recognize linear epitopes
in WB test (Table S3). Taken together, 2D4 and 18E4
might recognize some linear sites not exposed in sol-
ution-state particle but accessible to antibody binding
in case of VLPs coated in the microplate.
Epitope mapping of three HPV6 nAbs
The footprints of 5D3, 17D5, and 15F7 on the HPV6
capsid were delineated by projecting the density map
onto the surface of the model of the HPV6 particle
using RIVEM software [44]. According to these foot-
prints, the binding sites of Fab 5D3 cover five confor-
mationally close regions: K52, R53, A54, and N55 of
Figure 4. Cryo-EM reconstruction of the HPV6-Fab complexes. Representative cryo-EM images of the HPV6 PsV complexed with
5D3 (A), 17D5 (B), and 15F7 (C). (D, E, F) Central slice of the PsV-Fab density maps shown along icosahedral 2-fold, 3-fold, and
5-fold axes, respectively (white lines). (G, H, I) Density maps of complexes coloured according to the distance from the centre
of the capsid.
1728 X. Liu et al.
the BC loop; K169, T172, N173, P175, V176, Q177, and
A178 of the EF loop; E262, V263, E265, and P266 of the
FGa loop; V344, T345, and T346 of the HIa loop; and
S353 of the HIb loop (Figure 5J). Among these regions,
the FG loop plays a critical role in the interaction
between 5D3 and the HPV6 capsid, as indicated in
the binding assay using loop-swapped HPV6 VLPs
(Figure 1D, Table S2). For the binding of 17D5 Fab,
the DE loop (DEa: Y123, N128; DEb: G130, S131,
G132; DEc: N139) and the FG loop (N278 and R279)
are involved in the capsid-antibody interactions
(Figure 5K); this is consistent with the results of the
binding variations with loop-substituted HPV6 VLPs,
where the substitution of DEa, DEc, or the FGb loops
of HPV6 with those of HPV16 abrogates the binding
activity of mAb 17D5 with the VLPs (Figure 1D,
Table S2). As compared with the other two antibodies,
the binding regions of 15F7 span a greater number of
surface loops, including the DEb loop (N134, P135,
G136, Q137), DEc loop (N139), EF loop (K169,
V176, Q177, A178), FGa loop (E262, V263), FGb
loop (S276, G277, N278), HIa loop (V344, T345,
T346) and HIb loop (S347, S348, T349, S353)
(Figure 5L). These interaction sites overlap with
Figure 5. Binding interface and footprint of HPV6 nAbs. An asymmetric unit of the HPV6 PsV structure and crystal structure of a
murine antibody (PDB accession code 3RKD) were fitted to the cryo-EM density map (gray mesh). Light and heavy chains of the Fab
and the HPV6 L1 protein are coloured in blue, red and orange, respectively. (A, B, C) Zoomed-in view shows a pentavalent and the
neighboring hexavalent capsomers, as indicated by the pentagon and hexagons, respectively. (A) The numbers denote the six
different monomers of the icosahedral asymmetric unit on the map of the HPV6:5D3 complex. (D, E) A map of a pentamer with
different Fabs was extracted and fitted using the structure of the HPV6 particle and crystal structure of Fab. (B) The numbers denote
two different monomers of the pentavalent capsomer on the map of the HPV6:17D5 complex. (F) Close-up view of interface
between the Fab and capsomer. (G) Density map was superimposed with the above-mentioned crystal structure. (C) The numbers
denote five different monomers of the pentavalent capsomer on the map of the HPV6:15F7 complex. (H, I) The same density map
was superimposed with the above-mentioned crystal structures. A stereographic projection was used to show the surface of the
particles, where the polar angles θ and Φ represent latitude and longitude, respectively. (J, K, L) Footprints of three Fabs
(5D3,17D5,15F7) displayed by deep blue contour lines. The BC, DE, EF, FG, and HI surface loops of the HPV6 L1 protein are
shown in cyan, green, purple, salmon, and gray, respectively. The locations of the 2-fold and 3-fold icosahedral symmetry axes
are indicated as black ovals and triangles.
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regions clustered in the DEb, DEc, and EF loops, as
revealed in binding tests (Figure 1D, Table S2).
Discussion
Currently, most of the information regarding virus neu-
tralization centres around high-risk HPV types. For
instance, the classical neutralizing antibody,
HPV16.V5, has been extensively characterized through
structural analysis and immune assays for its neutraliz-
ation efficacy of the high-risk HPV16, whereas there
are few in-depth studies related to the conformational
epitopes of HPV6, the most abundant causative patho-
gen for genital warts. A previous study identified a
region spanning residues 49–54 on the L1 protein of
HPV6 as a neutralization site, using a CRPV/HPV6
hybrid L1 protein [28]. However, further detailed infor-
mation pertaining to the mode of neutralization and
how antibodies would be useful against this type of
HPV are lacking. Here, we use a well-characterized
anti-HPV6 monoclonal antibody panel [29] of several
potent neutralizing antibodies (Table S3) to explore in
detail the binding of neutralizing antibodies to HPV6.
Given the genotype-specific nature of most modes
of HPV neutralization, we employed chimeric HPV6-
16 VLPs bearing individual surface loop/subloop swap-
ping to roughly map the neutralization sites of HPV6.
This mode of analysis afforded the use of high-
throughput ELISA followed by cryo-EM reconstruc-
tion to precisely map the neutralization sites. However,
for HPV6:17D5 and HPV6:5D3, the binding modality
– in particular, the overlap of neighboring Fabs – while
allowing for binding to the capsid simultaneously, led
to a low binding affinity and potential capsid structure
perturbance that mitigated resolving a high-resolution
structure. By comparison, HPV6:15F7 resulted in a
high-resolution structure (Table S1) at least in part
due to the favourable binding of all Fabs without any
steric hindrance. Overall, we acquired three different
binding modes for the HPV6 nAbs – dispersive capsid
bound, top-centre-bound, and top-rim pentamer-
bound – and obtained precise neutralization sites
using the RIVEM method [44]. Moreover, our results
describe an unprecedented manner of binding for
nAb 15F7, as shown by the intensive clustering around
every pentamer. It should be mentioned that a pre-
viously described [16] crystal structure of HPV16L1
Figure 6. Proposed neutralization mechanism for mAbs against HPV6. HPV can attach to the host cell by binding to the primary
receptor, such as heparan sulfate proteoglycans (HSPGs) on the cell surface or laminin-332 in the ECM. The virus then likely under-
goes some conformational changes that expose the N-terminal amino acids of the minor L2 protein. Following furin cleavage of L2,
the virions transfer to secondary receptors and initiate cell entry. Neutralizing antibodies (nAbs) recognize the surface epitopes of
HPV. Some nAbs, like 10H1, 17D5, 11B10, and 5D3, block viral primary attachment to the ECM or cell surface. Others, such as 15F7,
do not interfere with cell binding but may neutralize HPV by interrupting viral transfer on the cell surface or by altering the actions
of secondary receptors responsible for internalization.
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bound with HSPG – deemed as a primary receptor
for numerous viruses [45] – suggested that the
region circumscribed by K54, K59, K278, K356,
K361, K442, and K443 was associated with viral
neutralization when using monoclonal antibodies
for which the footprint befalls or overlaps with
this region. Indeed, in the present study, we show
that nAb 5D3 appears to neutralize the virus by
interfering with HSPG attachment.
Viral neutralization is essential for organisms to
fight against various pathogens in vivo. Neutralization
mechanisms are usually related to antibody efficacy
and action space as a function of time in the host,
and are categorized pursuant to the perturbance, thus
pointing to the influence of different phases of virus
infection. Non-enveloped HPV infection is believed
to involve host cell attachment, entry and intracellular
trafficking, with the L1 major protein mediating attach-
ment to cell receptors, facilitating exposure of the L2
protein to furin, and enabling its subsequent enzymatic
cleavage, and finally, enabling the structural rearrange-
ment that triggers the entry process (Figure 6) [24]. In
this study, we show that nAb 5D3 recognizes a wide
region, covering loops BC, EF, FG, and HI, which over-
laps with the binding sites of HSPG, thereby encum-
bering viral attachment to both the ECM and the cell
surface. Thus, it is reasonable to infer that 5D3 neutral-
izes HPV infection by blocking virus attachment and
any sequential conformational changes that drive
further viral internalization. Unlike 5D3, a single
17D5 moiety engages with the centre of the pentamer
in a top-centered binding mode, as described pre-
viously by us for nAb HPV58.A12A3 [41]. The anti-
body footprints by this mode of binding mainly
situate a region of the DE loop that is distant from
the well-defined HSPG binding sites [23]. However,
unexpectedly, 17D5 both in full-length and Fab
forms could still prevent HPV6 PsVs from attaching
to cell surface, which suggests that 17D5’s binding
might induce conformation changes on or near
HSPG binding sites in its neutralization mechanism
(Figure 2B, Figure S6). Interestingly, the third nAb
we characterized in detail, 15F7, strongly binds
around each pentamer to confer potent neutralizing
efficacy in the neutralization assay but still allows
the virus to attach to the ECM and the cell surface
(Figure 1B). Thus, 15F7 may neutralize the virus
in post-attachment events (Figure 6) same as
HPV16.V5 antibody, although HPV16.V5 can block
viral attachment to ECM but allow engagement to
cellular surface [26].
Overall, we comprehensively characterized and
structurally mapped the major neutralization epitopes
of HPV6, our results suggest two neutralization mech-
anisms for HPV6 nAbs: most nAbs neutralize HPV6
by interfering with the attachment phase of virus
infection, whereas some nAbs (e.g. 15F7) affect virus
penetration and entry into the host cell; albeit, in
such cases, the Ab-bound virus still attaches to the
ECM and/or the cell surface (Figure 6). It should be
noted that the post-attachment neutralization of
nAb 15F7 – a unique cluster-binding around each
pentamer that allows cell receptor to bind to the
unoccupied regions of the virus, but abrogates the
Ab-bound virus from cell entry – might define a
potential alternative mode of classic HPV inhibition
by the attachment blocking of a non-HSPG cell recep-
tor. These findings will expand our knowledge on
HPV immunology and virology for the benefit of
vaccine and antivirus design.
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